Clinical trials: Diabetes Mellitus With Gastrointestinal Symptoms
Gastrointestinal Hemorrhage, Diabetes Complications
Therapeutic Conflicts and Multimorbidity
Clinical practice guidelines do not take into account multimorbidity and various potential therapeutic conflicts. Identifying and quantifying therapeutic conflicts is crucial in multimorbid patients having more than two acute or…
- Conditions
- Gastrointestinal Hemorrhage, Diabetes Complications, Multimorbidity
- Trial name
- NCT02928939
- Testing
- drug-drug or drug-disease interaction
- Where
- Switzerland
- Volunteers
- 1,101 people
- Sponsor
- University of Zurich
Liver Cirrhosis With Diabetes
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
This study was a prospective, interventional, two-part pilot clinical study conducted over 3 months on cirrhotic patients with diabetes mellitus and diabetic neuropathy, evaluating the real-world applicability of selected…
- Trial name
- NCT07439536
- Testing
- Sitagliptin (Januvia), Sitagliptin (JANUVIA®), Duloxetine (60 mg) once daily
- Where
- Egypt
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Gastric Pathophysiology in Diabetes
This is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. The investigators aim to examine the stomach with various measurement devices to gain information about its…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Functional Dyspepsia, Gastroparesis
- Trial name
- DiaFLIP (NCT06068114)
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
Diabetes Mellitus, Gastroparesis With Diabetes Mellitus
Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes
This study will assess changes in glycemic control in 40 patients with diabetes who undergo per-oral pyloromyotomy (POP) for medically refractory gastroparesis.
- Conditions
- Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis
- Trial name
- NCT04696159
- Testing
- Pyloromyotomy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Matthew Allemang
Overweight and Obesity, Type2 Diabetes
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by…
- Conditions
- Overweight and Obesity, Type2 Diabetes, NAFLD
- Trial name
- NCT04812262
- Testing
- DD01
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
Gastroparesis, Diabetic Gastroparesis
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus
- Trial name
- NCT00845858
- Testing
- metoclopramide
- Where
- 65 sites in United States
- Volunteers
- 287 people
- Sponsor
- Evoke Pharma
Type 2 Diabetes, Obesity
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).
- Conditions
- Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07570810
- Testing
- CS0159, Semaglutide
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Fatty Liver, Overweight/Obesity
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases.
- Conditions
- Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
- Trial name
- Test2Func (NCT03851627)
- Testing
- Testosterone Undecanoate
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Alexandra Kautzky-Willer
Diabetic Gastroparesis
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
The objective of the study is in subjects with Insulin Treated Diabetes Mellitus type 1 or 2 and gastroparesis: validate radiopaque markers with fluoroscopy with gastric scintigraphy method study the difference of metabolic…
- Trial name
- NCT01557296
- Testing
- dietary treatment: food of small particle size, Validate X-ray diagnostic method., Can the motility be improved
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Göteborg University
Fatty Liver, Non-Alcoholic Steatohepatitis
A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic…
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Trial name
- Aramchol_005 (NCT02279524)
- Testing
- Aramchol
- Where
- 78 sites in United States, Chile and 9 more
- Volunteers
- 247 people
- Sponsor
- Galmed Research and Development, Ltd.
Diabetes Mellitus
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
The drug effects will be studied after a single dose of 50 milligram (mg) albiglutide and a single dose of 10 microgram exenatide, to gain insight into the central mechanisms of nausea associated with Glucagon-like peptide-1…
- Trial name
- NCT02802514
- Testing
- Albiglutide 50mg, Exenatide 10microgram
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Gastrointestinal Symptoms in Children With Type 1 Diabetes
This cross-sectional study aims to assess the frequency and types of gastrointestinal symptoms in children with type 1 diabetes mellitus compared with age- and sex-matched healthy controls.
- Trial name
- NCT07845175
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Diabetes Mellitus, Type 2, Metformin Adverse Reaction
Probiotics in Metformin Intolerant Patients With Type 2 Diabetes
Metformin, the first-line drug in the treatment of type 2 diabetes (T2DM), may cause dose dependent undesirable side-effects like diarrhea, abdominal pain, nausea or bloating which may affect up to 20 % of patients treated with…
- Trial name
- ProGasMet (NCT04089280)
- Testing
- Sanprobi Barrier-multispecies probiotic
- Where
- Poland
- Volunteers
- 37 people
- Sponsor
- Medical University of Silesia
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Hepatitis C
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
The aim of this study is to investigate the efficacy and safety of an insulin-sensitizer (Actos) added to a standard Pegasys/Copegus combination therapy of chronic hepatitis C in patients who have previously failed a…
- Trial name
- NCT00433069
- Testing
- Pioglitazone, Interferon Alfa-2a, Ribavirin
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University Hospital, Geneva
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
Glucagon is secreted from pancreatic alpha-cells in response to protein-rich meals and during hypoglycemia. A physiological feedback system exists between the liver and the pancreatic alpha cells termed the liver-alpha cell axis…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Glucagon Resistance, Type 1 Diabetes, Obesity
- Trial name
- GLUSENTIC (NCT04907721)
- Testing
- Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon
- Where
- Denmark
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Gastroparesis, Gastroparesis Postoperative
Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of Gastroparesis
Gastroparesis is a burdensome condition that is caused by abnormal motor function of the stomach that results in delayed gastric emptying.
- Conditions
- Gastroparesis, Gastroparesis Postoperative, Gastroparesis Nondiabetic, Gastroparesis With Diabetes Mellitus
- Trial name
- NCT06661668
- Testing
- Gastric pacemaker (Enterra system) implantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Evangelic Hospital Kalk Cologne